|
PSME3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.66050004038965E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.88539999565774E-08 |
| Normal-vs-Stage2 |
1.739750E-02 |
| Normal-vs-Stage3 |
2.52609999584763E-08 |
| Normal-vs-Stage4 |
3.71460000536672E-08 |
| Stage1-vs-Stage2 |
5.459700E-02 |
| Stage1-vs-Stage3 |
2.855600E-01 |
| Stage1-vs-Stage4 |
1.435650E-01 |
| Stage2-vs-Stage3 |
1.609530E-02 |
| Stage2-vs-Stage4 |
9.103100E-03 |
| Stage3-vs-Stage4 |
5.440600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.53739998299108E-09 |
| Normal-vs-AfricanAmerican |
2.519500E-03 |
| Normal-vs-Asian |
1.593190E-04 |
| Caucasian-vs-AfricanAmerican |
5.648600E-01 |
| Caucasian-vs-Asian |
9.845400E-01 |
| AfricanAmerican-vs-Asian |
6.704400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.01430000351866E-09 |
| Normal-vs-Female |
9.96169999822882E-08 |
| Male-vs-Female |
7.845700E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.58139999989682E-07 |
| Normal-vs-Age(41-60Yrs) |
4.76329999887781E-08 |
| Normal-vs-Age(61-80Yrs) |
8.40100000010224E-07 |
| Normal-vs-Age(81-100Yrs) |
8.170500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.798400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.709800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.710000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.887600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.809800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.529200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.379000E-01 |
| Classical-VS-Follicular |
5.551200E-01 |
| Classical-VS-Other |
2.292000E-02 |
| Classical-VS-Normal |
1.54269999996792E-07 |
| Tall-VS-Follicular |
4.000400E-01 |
| Tall-VS-Other |
1.570840E-01 |
| Tall-VS-Normal |
1.8720899999991E-05 |
| Follicular-VS-Other |
8.633600E-02 |
| Follicular-VS-Normal |
2.12139999999916E-05 |
| Other-VS-Normal |
1.793440E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.25259999994576E-06 |
| Normal-vs-N1 |
5.76580000410942E-08 |
| N0-vs-N1 |
2.903800E-02 |
|
|
